Investigating the protective effect of vitamin B2 in patients with breast cancer

Investigating the protective effect of riboflavin on taxane-induced neurotoxicity

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N250

Enrollment

Registered

2025-05-26

Start date

2025-06-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: In the intervention group, breast cancer patients will receive 20 mg of riboflavin in capsule form for 12 weeks in addition to their paclitaxel chemotherapy regimen. Intervention 2: Th

Eligibility

Sex/Gender

All

Age

17 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent Age 17 and up Patients diagnosed with malignant breast tumors Patients eligible to receive weekly paclitaxel chemotherapy regimen

Exclusion criteria

Exclusion criteria: Patients with a history of peripheral and diabetic neuropathy; a history of cognitive disorders; a history of alcohol use; a history of mental disability or severe mental illness.

Design outcomes

Primary

Measure	Time frame
Peripheral neuropathy. Timepoint: 12 and 24 weeks after the start of the intervention. Method of measurement: Questioning the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohana Dehghan

Kermanshah University of Medical Sciences

m.dehghan1020@yahoo.com+98 83 3427 4618

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026